Agreement between HADS classifications and single-item screening questions for anxiety and depression: a cross-sectional survey of cancer patients

- Mackenzie, L. J., Carey, M. L., Sanson-Fisher, R. W., D'Este, C. A., Paul, C. L., Yoong, S. L.

Biomarkers in melanoma

- Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

- Regan, M. M., Walley, B. A., Spazzapan, S., Parmer, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Pagani, O., Francis, P. A., Fleming, G. F., Lang, I., Gomez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M.

Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making

- Milioli, H. H., Tishchenko, I., Riveros, C., Sakoff, J., Berretta, R., Moscato, P.

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

- Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

- Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., Australian New Zealand Breast Cancer Trials Group

Immunotherapy of distant metastatic disease

- Schadendorf, D., Algarra, S. M., Schachter, J., Hersey, P., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A. M. M., Espinosa, E., Guo, J., Hauschild, A., Petrella, T.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

- Folprecht, G., Pericay, C., Ackland, S. P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J. R., Saunders, M. P., Thomas, A., Lopez Lopez, R., Roh, J. K., Chistyakov, V., Höhler, T., Kim, J. - S., Hofheinz, R. D.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report

- Karlsson, P., Cole, B. F., Forbes, J. F., Gelber, R. D., Goldhirsch, A., Gruber, G., Chua, B. H., Price, K. N., Lindtner, J., Collins, J. P., Kovacs, A., Thurlimann, B., Crivellari, D., Castiglione-Gertsch, M.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013

- Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial

- Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, E. H., Watson, D. I., Ackland, S. P., Martin, J. M., Burge, M., Finch, R., Karapetis, C. S., Shannon, J., Nott, L. M., Varma, S., Marx, G., Falk, G. L., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G.

Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103⁺ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials

- Rischin, D., Mehanna, H., Porceddu, S., Wratten, C., Robinson, M., Solomon, B. J., Young, R. J., Bressel, M., Dunn, J., Corry, J., Soni, P., Fulton-Lieuw, T., Iqbal, G., Kenny, L.

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

- Chen, J., Jiang, C. C., Jin, L., Zhang, X. D.

Small molecules and targeted therapies in distant metastatic disease

- Hersey, P., Bastholt, L., Schadendorf, D., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C.

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015

- Coates, A. S., Winer, E. P., Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Ejlertsen, Bent, Goldhirsch, A., Forbes, John F., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José

The sequential use of endocrine treatment for advanced breast cancer: where are we?

- Barrios, C., Forbes, J. F., Hudis, C., Robertson, J. F. R., Jonat, W., Conte, P., Gradishar, W., Buzdar, A., Gelmon, K., Gnant, M., Bonneterre, J., Toi, M.

Utility of adjuvant systemic therapy in melanoma

- Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., Mackie, R. M., Hauschild, A.

Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

- Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.